Business Context and Reporting Period
This filing is a Form 13F-HR submitted by Takeda Pharmaceutical Co Ltd, an institutional investment manager based in Tokyo, Japan. The report covers the calendar quarter ended March 31, 2025, and was signed on May 7, 2025, by Amit Singh, Senior Vice President and Head of Treasury.
Key Financial Metrics
As a Form 13F filing, this document discloses equity holdings rather than the company's operational financial performance. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity for Takeda Pharmaceutical Co Ltd is not present in this text.
- Total Value of Reported Holdings: $16,194,016
- Number of Holdings Reported: 12
- Other Included Managers: 1 (Takeda Vaccines, Inc.)
Material Changes
The filing text does not provide comparative data for the prior period; therefore, material changes in holdings value or composition cannot be determined from this summary.
Guidance, Outlook, and Risks
This filing type does not contain management commentary, forward-looking guidance, risk factors, or contingencies regarding the company's business operations. It strictly lists securities held with voting or dispositive authority.
Investor Verification Checklist
- Verify the specific 12 equity positions held by Takeda Pharmaceutical Co Ltd in the full schedule of the filing.
- Confirm the relationship and reporting overlap with the included manager, Takeda Vaccines, Inc. (File No. 028-24939).
- Note that the total reported value ($16.2 million) represents only the specific equity holdings disclosed in this 13F, not the total assets or market capitalization of Takeda Pharmaceutical Co Ltd.